Skip to content
Disclosery

BIOS Capital Management, LP

Follow

13F filer, CIK 1813845, Fort Worth, TX

BIOS Capital Management, LP reported $41,671,192 across 6 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001813845-26-000004

Period
2026-06-30
Reported value
$41.7M
Holdings
6
Top 10 weight
100%
New
0
Sold out
0

Part of the filer group BIOS Capital Management, LP

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
RNTXadded+1,000,000$1.04M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
LTRNreduced-615,038-$2.56M
INABreduced-86,848-$122K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001813845-26-000004, largest first. % of portfolio is the value over $41,671,192, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ACTUACTUATE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 9,893,651 shares; 2025Q1: 9,893,651 shares; 2025Q2: 9,965,079 shares; 2025Q3: 10,049,996 shares; 2025Q4: 10,049,996 shares; 2026Q1: 10,049,996 shares; 2026Q2: 10,049,996 shares 10,049,996$15.4M36.9%0Timeline
IRDOPUS GENETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 995,249 shares; 2025Q1: 995,249 shares; 2025Q2: 3,683,429 shares; 2025Q3: 3,683,429 shares; 2025Q4: 3,683,429 shares; 2026Q1: 3,683,429 shares; 2026Q2: 3,683,429 shares 3,683,429$15.1M36.33%0Timeline
CGTXCOGNITION THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 6,000,000 shares; 2025Q1: 6,000,000 shares; 2025Q2: 6,000,000 shares; 2025Q3: 6,000,000 shares; 2025Q4: 6,000,000 shares; 2026Q1: 6,000,000 shares; 2026Q2: 6,000,000 shares 6,000,000$6.9M16.56%0Timeline
RNTXREIN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 1,690,751 shares; 2025Q1: 1,690,751 shares; 2025Q2: 1,690,751 shares; 2025Q3: 1,690,751 shares; 2025Q4: 1,690,751 shares; 2026Q1: 1,982,375 shares; 2026Q2: 2,982,375 shares 2,982,375$3.1M7.44%+1,000,000Timeline
LTRNLANTERN PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: 1,207,709 shares; 2025Q1: 1,207,709 shares; 2025Q2: 1,075,952 shares; 2025Q3: 1,015,715 shares; 2025Q4: 1,009,507 shares; 2026Q1: 864,435 shares; 2026Q2: 249,397 shares 249,397$1.04M2.5%-615,038Timeline
INABIN8BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 253,417 shares; 2026Q1: 167,805 shares; 2026Q2: 80,957 shares 80,957$114K0.27%-86,848Timeline

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001813845-26-000004 base2026-08-14acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001813845-26-000004 Quarter ended 2026-06-302026-08-14acceptance time not in the bulk data set
13F-HR 0001813845-26-000003 Quarter ended 2026-03-312026-05-13acceptance time not in the bulk data set
13F-HR 0001813845-26-000002 Quarter ended 2025-12-312026-02-13acceptance time not in the bulk data set
13F-HR 0001104659-25-110482 Quarter ended 2025-09-302025-11-12acceptance time not in the bulk data set
13F-HR 0001104659-25-076893 Quarter ended 2025-06-302025-08-12acceptance time not in the bulk data set
13F-HR 0001104659-25-048606 Quarter ended 2025-03-312025-05-14acceptance time not in the bulk data set
13F-HR/A 0001104659-25-014450 Quarter ended 2024-12-312025-02-18acceptance time not in the bulk data set
13F-HR 0001104659-25-010964 Quarter ended 2024-12-312025-02-10acceptance time not in the bulk data set